We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • Drug Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Device Products
    • Books
    • Books Library
    • Events
    • Form 483s
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » European Commission Approves Opioid Dependence Implant

European Commission Approves Opioid Dependence Implant

June 27, 2019

Titan Pharmaceuticals and Molteni’s Sixmo (buprenorphine) subdermal implant for treating opioid addiction has earned European regulatory approval.

The device is now cleared in all European member states as a substitute treatment for clinically stable adults who require no more than eight milligrams of sublingual buprenorphine a day.

The subdermal implant, which delivers buprenorphine at a continuous rate for six months following insertion, received FDA approval in 2016 under the name Probuphine.

View today's stories

Medical Devices Submissions and Approvals

Upcoming Events

  • 10Jan

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 12Feb

    Increase Compliance, Reduce Risk with Integrated Digital Solutions: Create a Connected System and Streamline...

  • 17Mar

    FDA Data Integrity: For Device and Pharma Firms, and Their Suppliers

  • 19Mar

    SOPs and Policies for the 21st Century: Why Less is More

  • 20Apr

    17th Annual Medical Device Quality Congress

Featured Products

  • Biological-risk-eval-and-mngmnt-for-md-130x160

    Biological Risk Evaluation and Management for Medical Devices

  • Gmp-inspection-preparation-checklist-130x160

    GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • Clearancestamp_gray

    FDA Clears Lymphedema Assessment Platform for Expanded Indication

  • Herontherapeutics_logo

    Health Canada Grants Priority Review for Heron’s Non-Opioid Pain Treatment

  • Fda_logo_blue_2016

    Senate Confirms Stephen Hahn as Next FDA Commissioner

  • Healthcanada_logo

    Health Canada Approves Boehringer Ingelheim’s Ofev for Systemic Sclerosis

New!

17th Medical Device Quality Congress

Learn More Here
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578.

Copyright © 2019. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing